Trial Profile
A retrospective study to evaluate clinical outcomes with first-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Mar 2019
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 11 Mar 2019 New trial record
- 16 Feb 2019 Results presented at the 2019 Genitourinary Cancers Symposium